title: Estrogen therapy in a male patient with chronic hepatitis C and irradiation-induced testicular dysfunction.
abstract: We report an 18-year-old male patient who developed chronic hepatitis C after blood transfusion and had testicular dysfunction after irradiation for a testicular relapse of childhood acute lymphocytic leukemia after cessation of maintenance therapy, and the initiation of testosterone replacement therapy at puberty. Concomitant administration of estradiol resulted in a reduction in serum alanine aminotransferase and ferritin levels and hepatic iron concentration and staining after 2 years of estrogen therapy, although interferon therapy was withdrawn because of adverse effects. This observation suggests that endogenous estradiol may play a beneficial role in male patients with chronic hepatitis C.
authors: Second Department of Internal Medicine, Tokushima University School of Medicine.
authors: I
authors: I
authors: Shimizu
authors: T
authors: T
authors: Omoya
authors: Y
authors: Y
authors: Kondo
authors: Y
authors: Y
authors: Kusaka
authors: A
authors: A
authors: Tsutsui
authors: H
authors: H
authors: Shibata
authors: H
authors: H
authors: Honda
authors: N
authors: N
authors: Sano
authors: S
authors: S
authors: Ito
mesh_terms: D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy; D003094:Collagen / Q000032:analysis; D003131:Combined Modality Therapy; D004958:Estradiol / Q000031:analogs & derivatives* / Q000172:deficiency / Q000502:physiology / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005293:Ferritins / Q000032:analysis; D005640:Follicle Stimulating Hormone / Q000097:blood; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007501:Iron / Q000032:analysis; D017254:Leukemic Infiltration / Q000532:radiotherapy; D008099:Liver / Q000737:chemistry / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000532:radiotherapy; D011832:Radiation Injuries / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects*; D011994:Recombinant Proteins; D013733:Testicular Diseases / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D013737:Testis / Q000473:pathology / Q000528:radiation effects; D013739:Testosterone / Q000031:analogs & derivatives* / Q000172:deficiency / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013739:Testosterone; D004958:Estradiol; C004648:testosterone enanthate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003094:Collagen; D005293:Ferritins; D007501:Iron; D000410:Alanine Transaminase